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Abstract 24 
Promyelocytic leukemia (PML) proteins have been implicated in antiviral responses but PML and 25 
associated proteins are also suggested to support virus replication. One isoform, PML-II, is required 26 
for efficient transcription of interferon and interferon-responsive genes. . We therefore investigated 27 
the PML-II contribution to human adenovirus 5 (Ad5) infection, using shRNA-mediated knock-down. 28 
HelaΔII cells showed a 2 - 3 fold elevation in Ad5 yield, reflecting an increase in late gene expression. 29 
This increase was found to be due in part to the reduced innate immune response consequent upon 30 
PML-II depletion. However the effect was minor because the viral E4 Orf3 protein targets and 31 
inactivates this PML-II function. The major benefit to Ad5 in HelaΔII cells was exerted via an increase 32 
in HSP70; depletion of HSP70 completely reversed this replicative advantage. Increased Ad5 late 33 
gene expression was not due either to the previously described inhibition of inflammatory responses 34 
by HSP70 or to effects of HSP70 on major late promoter or L4 promoter activity but might be linked 35 
to an observed increase in E1B 55K, as this protein is known to be required for efficient late gene 36 
expression. The induction of HSP70 by PML-II removal was specific for the HSPA1B gene among the 37 
HSP70 gene family and thus was not the consequence of a general stress response. Taken together, 38 
these data show that PML-II, through its various actions, has an overall negative effect on the Ad5 39 
life-cycle. 40 
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Introduction 42 
The promyelocytic leukemia (PML) gene encodes a series of protein isoforms via alternative splicing 43 
(Jensen et al., 2001). Most of these contribute to the formation of PML nuclear bodies (PML-NB) that 44 
also transiently or permanently include many other proteins (Van Damme et al., 2010). PML proteins 45 
and/or PML-NB are implicated in a wide range of cellular functions, including innate and intrinsic 46 
immune responses (Bernardi & Pandolfi, 2007; Geoffroy & Chelbi-Alix, 2011). The PML gene itself is 47 
an interferon-stimulated gene (ISG) (Chelbi-Alix et al., 1995; Stadler et al., 1995), which suggests 48 
PML might be an effector of IFN responses. PML isoform II (PML-II) in particular is also required for 49 
the effective induction of IFNβ and ISG expression, which it achieves by promoting the assembly of 50 
functional transcription complexes at target promoters (Chen et al., 2015; Kim & Ahn, 2015). Thus 51 
this PML isoform can act upstream of IFN production to create a feed-forward loop that potentiates 52 
type I IFN responses.  53 
PML-NBs are intimately associated with the replication cycles of nucleus-replicating DNA viruses. 54 
Incoming viral genomes are found located in close proximity to PML-NBs (Ishov & Maul, 1996) and, 55 
for herpes simplex virus type 1 (HSV-1), PML-NBs have been shown to disassemble and reform close 56 
to the site of virus entry into the nucleus (Everett & Murray, 2005), suggestive of an early response 57 
by the cell to infection. During infection, PML-NBs are then targeted by proteins encoded by a wide 58 
variety of viruses (Leppard & Dimmock, 2006; Leppard & Wright, 2012). These findings fit a model in 59 
which PML-NBs or their components are broadly antiviral and hence viruses have evolved functions 60 
to disrupt these activities in order to favour virus replication. Alternatively, and not mutually 61 
exclusively, the interaction of viruses with PML-NB may have been selected to favour the virus, with 62 
disruption of PML-NBs liberating proteins that act to increase virus production (Berscheminski et al., 63 
2014).  64 
One well-characterized example of PML-NB disruption is the action of herpes simplex virus type 1 65 
(HSV1) ICP0 protein (Maul & Everett, 1994). Supporting an involvement of PML in IFN responses, 66 
HSV1 ICP0 mutants have a significant growth defect and attenuated pathogenicity in mice and both 67 
of these properties are substantially recovered in animals that are deficient in IFN responses 68 
(Halford et al., 2006; Leib et al., 1999); the ability of IFN to inhibit growth of ICP0 mutants in cell 69 
culture is also greatly reduced when PML-null or knock-down cells are used (Chee et al., 2003; 70 
Everett et al., 2008b). However, PML and other PML-NB components are also directly inhibitory to 71 
HSV1 independent of IFN (Everett et al., 2008a; Everett et al., 2008b), with PML-I and PML-II being 72 
particularly implicated (Cuchet et al., 2011). More recently, PML-II was also found to be the most 73 
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potent inhibitor, among the six nuclear PML isoforms, of transduction by a recombinant parvovirus 74 
AAV-2 vector (Mitchell et al., 2014). 75 
Human adenovirus type 5 (HAdV-C5, Ad5) infection also targets PML, rearranging it from PML-NB 76 
into track-like structures (Carvalho et al., 1995; Doucas et al., 1996); other PML-NB components are 77 
also redistributed, including some into virus replication centres (Berscheminski et al., 2014; Doucas 78 
et al., 1996). The Ad5 E4 Orf3 protein, which forms nuclear tracks by self-association (Ou et al., 2012; 79 
Patsalo et al., 2012), acts directly on PML-II, binding to its unique C-terminal domain to cause the 80 
redistribution of all PML isoforms (Hoppe et al., 2006; Leppard et al., 2009). Functionally, E4 Orf3 is 81 
necessary for Ad5 to replicate in the face of a pre-established IFN response (Ullman et al., 2007) and 82 
E4 Orf3 also disrupts the intrinsic antiviral effects of PML and another PML-NB component, Daxx 83 
(Ullman & Hearing, 2008). Taken together, these observations support the idea that the E4 Orf3 84 
interaction with PML-II opposes antiviral responses so as to favour productive viral infection, which 85 
fits well with the more recent finding that PML-II is needed for a robust type 1 IFN response (Chen et 86 
al., 2015). However, it has also been reported that PML-II serves a positive function during Ad5 87 
infection (Berscheminski et al., 2013).  88 
In light of these findings, we investigated the circumstances under which PML-II could provide a 89 
positive or negative influence on Ad5 infection, and the mechanisms underlying these influences. 90 
Viral gene expression and replication were increased by the removal of PML-II within a background 91 
of ongoing expression of other PML isoforms, leading to an increase in virus yield. One factor in this 92 
increase was the reduction in the interferon type I response in PML- II depleted cells. The other 93 
more significant factor was the increased level of HSP 70 protein in PML-II depleted cells, which was 94 
found to support elevated Ad5 gene expression. 95 
Results 96 
Stable knockdown of PML-II in Hela cells. To investigate the effect of PML-II on the well-97 
characterised Ad5 productive infection of Hela cells, we first generated PML-II knockdown Hela cells 98 
(HelaΔII) by lentiviral shRNA transduction, along with matched empty vector cells (HelaEV). HelaΔII 99 
cells were fully viable in long-term culture, showed similar morphology to both parental Hela cells 100 
and HelaEV cells (Fig. 1a) and grew at only a slightly slower rate than HelaEV cells under puromycin 101 
selection. HelaΔII cells showed significant reductions in PML-II mRNA (Fig. 1b) and protein (Fig. 1c). 102 
These cells also displayed functional knockdown of PML-II based on their reduced ability to express 103 
IL-6 and ISG56 (Fig. 1d), which was shown previously to depend on the presence of PML-II (Chen et 104 
al., 2015). 105 
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Depletion of PML-II increases the productivity of Ad5 infection. To establish the effect of PML-II on 106 
Ad5 infection, HelaΔII and HelaEV cells were infected in parallel with wild-type (wt) Ad5. Looking at 107 
protein expression over a time course, there was a strikingly higher level of late protein expression in 108 
HelaΔII cells (Fig. 2a); with an exposure selected to avoid grossly overexposing the HelaΔII lane, late 109 
proteins in the HelaEV cells were barely detectable. In contrast, expression of the early protein E2A 110 
72K DNA binding protein (DBP) was much less affected by the removal of PML-II though the E1B 55K 111 
protein was, by the late stage of infection (24 h p.i.), significantly increased (Fig. 2a). The expression 112 
of late proteins in HelaEV cells was similar to that in untransduced standard Hela cells (Fig 2b), 113 
confirming that the difference between HelaΔII and HelaEV infections was not due to any 114 
unexpected negative effect of introducing the retroviral vector alone in HelaEV cells. The effect of 115 
PML-II depletion on viral gene expression was confirmed and quantified by flow cytometry (Fig. 2c); 116 
both the proportion of cells positive for late proteins and their mean fluorescence intensity were 117 
increased in HelaΔII cells. The increased late protein expression in HelaΔII cells was reflected in a 2-3 118 
- fold higher virus yield/cell as compared with HelaEV cells, measured at 24 h and 48 h post-infection 119 
(Fig. 2d). 120 
Lack of IFN response partially explains the beneficial effect of PML-II depletion. Infection by Ad5 is 121 
intrinsically an IFN response-inducing event, with both virus entry itself and later gene expression 122 
events triggering interferon and inflammatory signalling (Hartman et al., 2007; Hendrickx et al., 123 
2014; Zhu et al., 2007). Since PML-II plays an important role in the activation of an IFN response 124 
(Chen et al., 2015), we considered the possibility that, even though Ad5 encodes functions that 125 
inhibit the IFN response in various ways, the beneficial effect on Ad5 infection of PML-II removal 126 
might nonetheless arise because of the consequent further defect in the IFN response. To test this, 127 
we directly disabled the IFN response by knockdown of IRF3, which is a key transcription factor in 128 
the induction of type 1 IFN responses (Au et al., 1995). Physical and functional depletion of IRF3 129 
from HelaEV cells (Fig 3a, b) increased Ad5 wt300 late gene expression by a modest amount (Fig. 3c), 130 
indicating that the Ad5 functions deployed to inhibit IFN responses are not 100% effective. However 131 
hexon expression under IRF3 knockdown in HelaEV cells was still very substantially lower than seen 132 
in HelaΔII cells, in which IRF3 knockdown had little additional effect. Thus, while some part of the 133 
benefit to Ad5 of PML-II removal reflects the loss of the IFN response, there is a significant additional 134 
component to be accounted for; this is considered further below.  135 
Ad5 E4 Orf3 inhibits PML-II function in the IFN response 136 
Ad5 E4 Orf3 binds PML-II directly (Hoppe et al., 2006) and is necessary for Ad5 replication in IFN-137 
treated cells, dependent on the presence of PML (Ullman & Hearing, 2008; Ullman et al., 2007), so 138 
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we asked whether this interaction also inhibited the natural IFN response to Ad5 infection. To 139 
determine whether viral expression of E4 Orf3 had any measurable effect on induction of type 1 IFN 140 
during infection, culture media from Ad5-infected HEK293 cells (Fig. 4a) or MRC5 normal human 141 
fibroblasts (Fig. 4b) were tested in plaque reduction assays using Semliki Forest virus, an IFN-142 
sensitive alphavirus. In both cell types, IFN activity was detected from an Orf3-deficient virus 143 
infection (inOrf3) while none was detected from wt300 or mock infections. Based on a calibration of 144 
the assay with recombinant IFNα, which showed inhibition from 0% to 100% by IFN in the range 0.1 145 
– 100 U/ml, inOrf3medium contained ~50 U/ml IFN. In separate experiments, IFN levels in infected 146 
HEK293 cell culture media were determined using an IFN-responsive reporter assay (Chen et al., 147 
2015). Again, IFN accumulation was detected only in inOrf3-infected cultures (Fig. 4c): amounts were 148 
equivalent to about 60 U/ml, in line with the estimate from the plaque-reduction assay. Thus, the 149 
presence of E4 Orf3 causes a measurable reduction in IFN production and secretion stimulated by 150 
Ad5 infection.  151 
To test whether E4 Orf3 protein alone was sufficient to inhibit IFN responses, we employed transient 152 
expression IFNβ promoter reporter assays. PML-IIΔRBCC is an artificially truncated form of PML-II 153 
that does not associate with PML-NB but retains E4 Orf3 binding (Leppard et al., 2009) and has 154 
increased ability to potentiate IFNβ promoter activation by inducers such as poly(I:C) (Chen et al., 155 
2015). E4 Orf3 fully reversed the increased response of the IFNβ promoter to poly(I:C) due to PML-156 
IIΔRBCC and further reduced reporter activity to levels below that of poly(I:C) stimulation in the 157 
absence of exogenous PML (Fig. 4d). This reduction below baseline reflected the contribution of 158 
endogenous PML-II, also an E4 Orf3 target, to the observed IFNβ promoter activation as, in the 159 
presence only of endogenous PML, added Orf3 also gave a dose-dependent inhibition of poly(I:C)-160 
stimulated reporter activity (Fig. 4e).  161 
To correlate the activity of E4 Orf3 in regulating IFNβ expression with its ability to bind PML-II, we 162 
compared the inhibitory effect of wild-type E4 Orf3 with that of selected Orf3 mutants (Hoppe et al., 163 
2006). Those mutants unable to bind PML-II (N82A, L103A) also failed to inhibit activation of the 164 
IFNβ promoter while mutants that retained PML-II binding (R100A, D105-L106A) had inhibitory 165 
activity similar to wild-type (Fig. 4e-i). Importantly, mutant D105-L106A uniquely retains PML-NB 166 
rearrangement activity whilst lacking the ability to disrupt the location of the MRN protein complex 167 
involved in DNA damage repair (Evans & Hearing, 2005). The retention of activity by this mutant thus 168 
clearly links the inhibitory effect of E4 Orf3 on IFN induction to its interaction with PML-II. 169 
The inhibitory effect of E4 Orf3 on PML-II function suggested that an Orf3-deficient virus should 170 
benefit more from the lack of PML-II in HelaΔII cells than a virus that was able to make Orf3. When 171 
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wt300 and inOrf3 late protein expression was compared in HelaEV cells (Fig. 5, lanes 2, 4), amounts 172 
were very similar, as expected (Huang & Hearing, 1989). As also shown previously, in Vero cells and 173 
human fibroblasts (Ullman et al., 2007), IFNα pre-treatment more severely inhibited inOrf3 than 174 
wt300 late protein synthesis in HelaEV cells (Fig. 5, lanes 3, 5). Importantly, removal of PML-II in 175 
HelaΔII cells largely abolished this difference in viral gene expression (Fig. 5, lanes 8, 10), confirming 176 
that PML-II is a significant functional target of E4 Orf3 during infection. However, contrary to 177 
expectation, wt300 gene expression benefitted more than that of mutant virus inOrf3 from PML-II 178 
removal (Fig. 5, lanes 2, 7 and 4, 9), see below. Collectively, our results show that PML-II is inhibitory 179 
to Ad5 infection in part through its role in the development of an IFN response and that E4 Orf3 180 
inhibits this function of PML-II.  181 
Enhanced growth of Ad5 in HelaΔII cells reflects overexpression of HSP70. A significant part of the 182 
benefit to Ad5 of PML-II depletion was independent of IRF3 and hence was not directly related to 183 
the IFN response (Fig. 3). Hence, late protein expression by either wt300 or inOrf3 was greater in 184 
HelaΔII cells than in equivalently treated HelaEV cells (Fig. 5). When studying stress responses in 185 
HelaΔII cells, we fortuitously observed that they displayed elevated levels of HSP70 mRNA and 186 
protein under normal growth conditions in comparison with HelaEV cells (Fig. 6a). HSP70 was also 187 
induced to a lower level by transient knock-down of PML-II in standard Hela cells (Fig. 6b), 188 
suggesting a direct link between loss of PML-II and HSP70 expression. Ad5 infection also induces 189 
HSP70 expression (Nevins, 1982) and, since it inhibits many other host genes whose activity is 190 
detrimental to infection (Zhao et al., 2003) and pre-existing HSP70 levels correlate with permissivity 191 
to Ad infection (Imperiale et al., 1984), we inferred that HSP70 might be the relevant positive factor 192 
for Ad5 growth in HelaΔII cells. To test this, hexon expression was compared in cells infected with or 193 
without HSP70 knock-down (Fig. 6c, d). Whilst HelaΔII cells showed substantially more hexon mRNA 194 
and protein than HelaEV cells when treated with a control siRNA, this difference was abolished by 195 
HSP70 siRNA treatment. Moreover, HSP70 siRNA also reduced hexon expression further from its 196 
lower base level in HelaEV cells. Thus, HSP70 contributes positively to Ad5 gene expression and the 197 
elevated expression of HSP70 in HelaΔII cells is a major factor in the increased efficiency of infection 198 
in these cells. The fact that wt300 gene expression benefitted more than that of mutant virus inOrf3 199 
from the high HSP70 environment in HelaΔII cells suggests that E4 Orf3 might be involved in the 200 
beneficial action of HSP70. 201 
The assay of HSP70 mRNA shown in Fig. 6a detects transcripts only from the two major heat-202 
inducible loci, HSPA1A and HSPA1B. However HSP70 encompasses a number of related proteins 203 
encoded by the HSPA gene family, only some of which are heat-inducible(Brocchieri et al., 2008). To 204 
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determine the specificity of HSP70 induction in HelaΔII cells, mRNA levels from several HSPA genes 205 
were assessed alongside HSP60 (HSPD gene family). As before, the HSP70 assay detected elevated 206 
mRNA levels in HelaΔII cells (Fig. 6e). Interestingly, despite the high level of similarity between the 207 
HSPA1A and HSPA1B genes (they encode identical 641 amino acid proteins), elevated HSP70 208 
expression was accounted for almost entirely by HSPA1B mRNA; there was little difference in 209 
expression of HSPA1A between the two cell types. In contrast to HSPA1, expression of HSPA5 mRNA, 210 
which encodes the endoplasmic reticulum chaperone GRP78 also known as BiP, was if anything 211 
slightly reduced by removing PML-II. Another HSP70 family member, HSPA6, which shows no basal 212 
expression but is induced by heat stress (Brocchieri et al., 2008), was detected only at low levels and 213 
was not induced by removal of PML-II; expression of HSP60 was also unaltered. Thus, the loss of 214 
PML-II leads to highly specific induction of the HSPA1B gene, providing HSP70 protein that supports 215 
enhanced Ad5 gene expression.  216 
Possible roles of HSP70 during Ad5 infection 217 
HSP70 has been shown previously to inhibit pro-inflammatory NF-κB signalling and hence both the 218 
production and the effect of TNF-α (Meng & Harken, 2002). Confirming that HSP70 had this effect in 219 
our system, we found that HSP70 knock-down significantly increased the expression of ISG56 in 220 
wt300-infected HelaEV cells (Fig. 7a). This suggested that HSP70 might favour Ad5 replication by 221 
limiting the induction of innate and inflammatory responses through NF-κB. TNFα is a known 222 
activator of NF-κB signalling and is considered to be inhibitory to virus infection (McFadden et al., 223 
2009). Ad5 infection can stimulate NF-κB signalling in several ways (Higginbotham et al., 2002; Pahl 224 
et al., 1996; Schmitz et al., 1996) while several viral E3 gene products counteract TNFα activity 225 
(Gooding et al., 1988), suggesting NF-κB activation might be inhibitory to Ad5 infection. We 226 
therefore tested whether elevated HSP70 in HelaΔII cells enhanced Ad5 infection by inhibiting NF-227 
κB. Reasoning that exogenous TNFα would oppose such an effect and so reduce the benefit of PML-II 228 
removal, we analysed Ad5 late gene expression in HelaΔII cells with or without TNFα treatment (Fig. 229 
7b). However, TNFα actually modestly enhanced Ad5 late protein expression in both HelaΔII cells 230 
and HelaEV cells. The same effect was seen on hexon mRNA in HelaEV cells and this was potentiated 231 
by HSP70 knock-down (Fig. 7c), as expected if HSP70 limits pro-inflammatory signalling that is 232 
beneficial to the virus. We also tested the effect of QNZ, an inhibitor of NF-κB activation (Tobe et al., 233 
2003) and found that, consistent with the effect of TNFα treatment, QNZ reduced Ad5 late gene 234 
expression in both cell types (Fig. 7d). These data indicate that NF-κB signalling increases rather than 235 
inhibits Ad5 gene expression in our system and that HSP70 limits rather than increases this effect. 236 
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The beneficial effect on Ad5 infection of the high levels of HSP70 in HelaΔII cells must therefore be 237 
due to some other function of HSP70.  238 
HSP70’s principal role is as a chaperone: during heat-stress it stabilises partially denatured proteins 239 
to prevent aggregation and facilitate re-folding (Clerico et al., 2015). The Ad5 replication cycle 240 
involves both the disassembly and assembly of protein complexes, processes which might be 241 
facilitated by HSP70. Indeed, HSP70 interacts both with the hexon shell of Ad2 particles shortly after 242 
infection (Niewiarowska et al., 1992) and with fibre protein during the late phase of Ad5 infection 243 
(Macejak & Luftig, 1991), and has been implicated in uncoating and import of the genome into the 244 
nucleus (Saphire et al., 2000). We therefore examined whether increased HSP70 present in HelaΔII 245 
cells altered the subcellular location of hexon protein, as an indicator of possible effects on particle 246 
assembly. Prior depletion of HSP70 from these cells, as well as decreasing the overall level of hexon 247 
protein as already described, increased more than two-fold the cytoplasmic / nuclear ratio of hexon 248 
(Fig. 8a; quantitation under right panels) whereas it had little effect on the distribution of E1A or E2A 249 
DBP. This result suggests that HSP70 overexpression consequent on PML-II depletion may positively 250 
affect the assembly of progeny particles in the nuclear compartment and hence could contribute to 251 
the increased yield of virus.  252 
Any impact of HSP70 level on assembly cannot explain the effect of HSP70 on hexon mRNA levels 253 
(Fig. 6). This mRNA is produced by processing of transcripts from the major late promoter (MLP), 254 
which itself is positively influenced by L4-22K protein expressed from L4P which is activated at the 255 
onset of the late phase (Morris et al., 2010). We therefore tested the effect of HSP70 depletion on 256 
the activity of MLP and L4P luciferase reporters in Hela cells (Fig. 8b), but found that neither was 257 
significantly affected. Thus HSP70 does not increase directly the intrinsic activity of either promoter 258 
when taken out of the context of viral infection and must therefore affect late gene expression post-259 
transcriptionally or dependent on the infected cell environment. In this regard, we noted the 260 
increase in E1B 55K protein upon PML-II depletion in HelaΔII cells (Fig. 8c), a protein which is known 261 
to positively regulate Ad5 late mRNA nucleo-cytoplasmic transport and accumulation (Leppard, 262 
1998). HSP70 depletion in HelaΔII cells reversed this increase in E1B 55K (Fig. 8a), further suggesting 263 
that it could be significant in the elevation of late gene expression. 264 
Discussion 265 
Depletion of PML-II from Hela cells, a standard permissive cell line for Ad5, led to a substantial 2-3 266 
fold enhancement in virus yield. This was attributed largely to a general increase in late gene 267 
expression, our experiments focusing mainly on the major capsid protein hexon and its mRNA as an 268 
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example. Thus, PML-II has an overall inhibitory effect on Ad5 infection. Two factors were identified 269 
that contributed to the increased infectious productivity upon PML-II depletion: a reduction in IFN 270 
response and an increase in HSP70 expression, the latter being the predominant factor. Depletion of 271 
HSP70 from HelaΔII cells completely eliminated the advantage to hexon expression of PML-II 272 
removal whilst blocking the IFN response in HelaEV cells by a means other than PML-II depletion 273 
only somewhat increased the levels of viral late gene expression.  274 
Previously, Berscheminski and colleagues reported that PML-II was beneficial to Ad5 infection, in 275 
apparent contradiction to our findings (Berscheminski et al., 2013). They showed that PML-II 276 
potentiated transcriptional activation of a viral early promoter by the E1A 13S protein and that, in a 277 
cellular context where all PML proteins were depleted, the addition of exogenous PML-II enhanced 278 
virus yield about 3-fold. Comparing these findings with our own, it is important to note the 279 
differences in cell environment employed. PML-II function will be a composite of its free and PML-280 
NB associated activities. PML-V is the stable base of PML-NBs (Weidtkamp-Peters et al., 2008), with 281 
other isoforms and many other proteins associating with these bodies by protein - protein 282 
interactions including SUMO-SIM interactions (Bernardi & Pandolfi, 2007). In a PML-null cell, 283 
functions observed for added PML-II will be essentially those of its soluble nuclear form. Indeed, a 284 
mutated form of PML-II with reduced ability to associate with PML-NBs was more active than the 285 
wild-type in cooperating with E1A in the presence of endogenous PML (Berscheminski et al., 2013), 286 
suggesting that interactions with other PML isoforms limit this activity. The overexpressed PML-II 287 
will also potentially exceed the capacity of E4 Orf3 expressed upon infection to bind and inactivate 288 
it. In contrast, specific depletion of PML-II in an otherwise normal PML background demonstrates 289 
the combined net contribution of this protein to the Ad5 life-cycle in all its cellular contexts. Our 290 
finding that PML-II removal exerts an overall positive effect on Ad5 growth is therefore not in 291 
disagreement with this prior study but instead reveals a new aspect of the functional interaction of 292 
PML-II with the virus. Our findings are also consistent with an earlier study showing the importance 293 
of PML proteins generally in the inhibition of Ad5 by an established IFN response (Ullman & Hearing, 294 
2008). 295 
Although PML-II is necessary for an efficient IFN response (Chen et al., 2015), Ad5 gained only 296 
modest benefit from the loss of this response in HelaΔII cells. This finding is expected since the virus 297 
possesses several functions that collectively oppose IFN responses, so allowing infection to succeed 298 
even when the cell is capable of launching a response. First, E1A proteins inhibit both the expression 299 
of ISGs and the activation of IFNβ transcription (Ackrill et al., 1991; Reich et al., 1988). Second, E1B 300 
55K protein blocks the induction of a number of IFN-inducible genes and is required for efficient 301 
  
 
11 
 
replication in normal fibroblasts (Chahal et al., 2012). Third, E4 Orf3 protein is necessary for 302 
replication to proceed in permanent cell lines in the face of an established IFN response (Ullman et 303 
al., 2007), implying it negatively regulates that response. Fourth, VA RNA I inhibits the induction of 304 
an IFN-induced antiviral state by inhibiting protein kinase R (Kitajewski et al., 1986). Finally, activated 305 
STAT1 is sequestered in Ad replication centres (Sohn & Hearing, 2011). The further advantage to Ad5 306 
of an inherent lack of IFN response may arise because of the time it otherwise takes for virus-307 
encoded anti-IFN functions to become active. We directly tested the idea that E4 Orf3 would inhibit 308 
the IFN response via its targeting of PML-II, and showed that this was the case: wild-type E4 Orf3 309 
inhibited type 1 IFN induction whilst mutant forms unable to bind PML-II could not; E4 Orf3 mutant 310 
virus infection elicited more IFN than wild-type; and E4 Orf3 mutant virus late protein expression 311 
was more strongly inhibited by prior IFN treatment in cells with functional PML-II. E4 Orf3 is 312 
expressed in the early phase but takes time to accumulate. In the period prior to this, our data 313 
suggest that inhibition of IFN induction is incomplete. 314 
The principal factor in the enhanced growth of Ad5 in HelaΔII cells was the elevated level of HSP70. 315 
Investigating this, we observed a modest effect of HSP70 on Ad5 late protein nuclear accumulation 316 
that would favour progeny virus formation but this could not account for the significant 317 
enhancement of late gene expression. HSP70 expression/depletion in HelaΔII cells did however also 318 
affect the accumulation of the viral E1B 55K protein, which is known to regulate late mRNA 319 
accumulation and hence to increase late gene expression (Leppard, 1998). This increased amount of 320 
E1B 55K in the presence of elevated HSP70 may contribute to the observed elevation in late gene 321 
expression and virus yield under these conditions. HSP70 also opposes inflammatory responses 322 
(Meng & Harken, 2002); given the role of PML-II in regulating inflammatory gene expression we 323 
considered this to be a plausible basis for the positive effect of HSP70 on Ad5 growth. However, NF-324 
κB activation was actually modestly beneficial to late gene expression. Since, as reported, HSP70 325 
opposed this activation, HSP70 elevation cannot be benefitting Ad5 via effects on NF-κB. The 326 
positive effect of NF-κB on Ad5 was unexpected given that the virus encodes functions in its E3 327 
region that inhibit TNFα signalling and hence NF-κB activation (Burgert et al., 2002). However, 328 
although these functions will be important in vivo they are known to be dispensable for growth in 329 
culture. Thus the small increase in Ad5 gene expression when NF-κB is activated in cell culture 330 
should not imply that this response benefits the virus in vivo. 331 
The elevated level of HSP70 in PML-II depleted cells reflected a highly specific increase in mRNA 332 
derived from the HSPA1B gene, one of two intronless genes that are strongly heat-inducible 333 
members of the HSPA gene family. HSPA1A and HSPA1B are very similar even in their promoter 334 
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sequences (Brocchieri et al., 2008); their products are not normally distinguished in analyses of heat-335 
induced HSP70 expression. The specific upregulation of HSPA1B by PML-II depletion cannot be due 336 
to a general cell stress response, and in particular cannot be attributed to activation of the heat 337 
shock transcription factor, HSF, which regulates transcription of HSPA1A and HSPA1B as well as 338 
other classes of HSP (Singh et al., 2010). Thus, these results indicate a novel mechanism whereby the 339 
HSPA1B promoter is selectively activated. Interestingly, HSPA1A and HSPA1B are located within the 340 
MHC III region, between the gene clusters encoding MHC class I and II antigen where specific 341 
depletion of individual PML isoforms has been shown to have effects on chromatin architecture and 342 
gene expression (Kumar et al., 2007). Further work is needed to test whether HSPA1B induction by 343 
PML-II removal reflects a similar mechanism. 344 
HSP70 is also induced during Ad5 infection (Nevins, 1982) and, whilst virus infection might be 345 
considered a stress that would lead to generalized activation of HSP expression, this induction is 346 
actually specific to HSP70 (Phillips et al., 1991). These studies did not distinguish between HSPA1A 347 
and HSPA1B, which were not separately recognised at the time. HSP70 transcription is induced by 348 
the virus-coded transactivator, E1A 13S (Wu et al., 1986), which acts via the cellular CCAAT-box 349 
factor (CBF) and its binding site in the context of a specific TATA box (Lum et al., 1992; Simon et al., 350 
1988). In this way, induction is independent of HSF. The CBF site is also a target for p53-mediated 351 
inhibition of the HSP70 genes (Agoff et al., 1993), suggesting that E1A might disrupt this inhibition. 352 
HSP70 expression is also favoured by the viral E1B 55K / E4 Orf6 complex promoting HSP70 mRNA 353 
export to the cytoplasm (Moore et al., 1987). Since, as discussed, our study shows that HSP70 levels 354 
are also positively linked to E1B 55K accumulation, a feed-forward loop may be established that 355 
promotes efficient late gene expression. 356 
The induction of HSP70 during Ad infection may be linked with positive roles for this protein in the 357 
virus life cycle. The best documented of these, in viral uncoating (Saphire et al., 2000), may account 358 
for the modest increase in early gene expression seen in HelaΔII cells. However, this action must 359 
precede E1A-induced activation of HSP70 synthesis, suggesting that other roles may exist to justify 360 
this mechanism. This role also cannot account for the predominant effect on late rather than early 361 
gene expression that we observed. A study by White et al. suggested an involvement of HSP70 in 362 
nuclear events linked with PML during Ad2 infection (White et al., 1988). HSP70 was recruited from 363 
the cytoplasm into discrete nuclear structures that co-localized with E1A and which appeared similar 364 
to the reorganized PML tracks that are formed by E4 Orf3 (Carvalho et al., 1995; Doucas et al., 1996). 365 
Indeed, Carvalho et al. found a small fraction of E1A and, in a few infected cells, HSP70 located in 366 
these Orf3 / PML structures, evidence of a physical and/or functional link between HSP70 and PML 367 
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that might be related to our observations. Interestingly, our work suggests that the presence of E4 368 
Orf3 is required in order for Ad5 to benefit from the elevation of HSP70 that occurs in HelaΔII cells.  369 
Many other viruses induce and/or functionally interact with HSP70 (Santoro et al., 2010) suggesting 370 
a general importance of this protein to infection. The avian adenovirus CELO Gam1 protein causes an 371 
increase in both HSP70 and HSP40 that is needed for replication, and loss of Gam1 can be 372 
complemented by heat-shock (Glotzer et al., 2000). Gam1 is also responsible for the loss of PML 373 
from infected cells through an inhibition of sumoylation (Colombo et al., 2002), raising the possibility 374 
that HSP induction and PML loss are also linked in this system. Human cytomegalovirus, HSV1, 375 
vaccinia virus and some paramyxoviruses all induce HSP70 expression (Santoro et al., 2010). For 376 
HSV1, heat shock can complement deficiency in ICP0, the protein responsible for PML body 377 
disruption and PML degradation, (Bringhurst & Schaffer, 2006) while the same is true for E1A 378 
deficiency in Ad (Imperiale et al., 1984; Madara et al., 2005).  379 
In conclusion, we have shown that PML-II opposes productive Ad5 infection, in part by supporting 380 
innate immune responses but mainly due to a suppressive effect on HSP70 expression. Our study 381 
reveals a previously undefined activity for HSP70 in supporting Ad5 late gene expression and 382 
demonstrates an inhibitory effect of PML-II on HSP70 expression.  383 
Materials and Methods 384 
Generation of HelaΔII and HelaEV cell lines  385 
Hela cells were transduced with either lentiviral particles encoding an shRNA specific for PML-II or 386 
equivalent particles with no shRNA insert. The PML-II shRNA incorporated the active siRNA sequence 387 
described by (Kumar et al., 2007) which was used previously by our laboratory to achieve functional 388 
knock-down of PML-II (Chen et al., 2015). Lentiviral particles were generated using pLKO.1 (Moffat et 389 
al., 2006) following protocols supplied by the RNAi consortium (Addgene). Briefly, a double-stranded 390 
synthetic oligonucleotide corresponding to the shRNA was cloned into pLKO.1. Specific plasmid 391 
clones were verified by sequencing, then transfected with psPAX2 and pMD2.G packaging plasmids 392 
into HEK-293T cells using Transit LT-1 (Mirus) to produce VSV-G-pseudotyped particles. Particle 393 
stocks were then used to infect Hela cells and transduced cells were selected with 3 µg/ml 394 
puromycin.  395 
Antibodies and reagents 396 
Specific primary antibodies were: AdJLB1 rabbit antiserum to Ad5 late proteins (Farley et al., 2004); 397 
mouse monoclonal antibodies 2HX-2 to Ad5 hexon (Cepko et al., 1983), B6-8 to Ad5 E2A DNA 398 
binding protein (DBP) (Reich et al., 1983), and 2A6 to Ad5 E1B 55K (Sarnow et al., 1982); 399 
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monospecific anti-peptide sera reactive against PML-II (Xu et al., 2005), kindly provided by Prof K.-S. 400 
Chang, M.D. Anderson Cancer Center, University of Texas; FL-425 rabbit anti-IRF3 (SantaCruz); rabbit 401 
anti-HSP70 (StressMarq SPC-103C/D); and GA1R mouse anti-GAPDH (Thermo Scientific). Secondary 402 
antibodies were: Alexa488 - conjugated goat anti-mouse Ig (Life Technologies); horseradish 403 
peroxidase (HRP) - conjugated goat anti-mouse Ig (Sigma); and HRP-conjugated goat anti-rabbit Ig 404 
(SantaCruz). IFNα was from PBL Assay Science, TNFα from Invitrogen, poly(I:C) from Sigma and 6-405 
amino-4-(phenoxyphenylethylamino)quinazolin (QNZ) from Santa Cruz. siRNAs were: IRF3 (ID 3661, 406 
Qiagen); HSP70 (targets HSPA1A and HSPA1B, Ambion); and control B (Chen et al., 2015).  407 
Cell culture and virus infection 408 
HEK293, HEK293T, Hela and knock-down cell lines were maintained at 37 ˚C, 5% CO2 in Dulbecco’s 409 
modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS);  for maintenance 410 
purposes, HelaEV and HelaΔII cells were alternated between media containing or not containing 3 411 
µg/ml puromycin. VERO cells were maintained in DMEM supplemented with 5% FBS and MRC5 cells 412 
in 10% Eagle’s minimal essential medium supplemented with 10% FBS, 2mM L-glutamine and 1% 413 
non-essential amino acids. Cells were seeded at the appropriate density 24 h prior to the respective 414 
procedure. Light microscope images were recorded on an inverted microscope using a 5x objective. 415 
Virus stocks and experimental samples were titred in a fluorescent focus assay. Hela cell monolayers 416 
were infected in duplicate with serial dilutions of each stock, incubated at 37 ˚C, 5% CO2 for 16 h, 417 
then fixed and stained with antibody to E2A DBP to visualize fluorescent cells for counting. 418 
Experimental infections were carried out with wild-type Ad5 wt300 or E4 Orf3 mutant inOrf3 (Huang 419 
& Hearing, 1989) at a multiplicity of 5 fluorescence focus units (ffu) per cell unless otherwise 420 
indicated. siRNA transfections were performed with Lipofectamine 2000 (Invitrogen), using a ratio of 421 
1 μl reagent per 25 pmol siRNA. 422 
Protein and RNA analysis 423 
For total protein analysis, cells were lysed directly in SDS gel sample buffer. Cytoplasmic and nuclear 424 
fractions were generated by lysing cells in 0.67% (v/v) NP40, 10 mM NaCl, 1.5 mM MgCl2, 10 mM 425 
Tris.HCl pH7.5 for 10 min on ice, then nuclei were pelleted by low speed centrifugation; an equal 426 
volume of 2x SDS gel sample buffer was added to the supernatant (cytoplasmic fraction). Crude 427 
nuclei were washed once in PBS, pelleted as before and then lysed in SDS gel sample buffer (nuclear 428 
fraction). Proteins were separated by electrophoresis on 10% SDS polyacrylamide gels and detected 429 
by western blotting as previously described (Lethbridge et al., 2003). For flow cytometry analysis, 430 
single cell suspensions produced by trypsinization were fixed on ice with 10% (v/v) formalin in PBS 431 
for 20 min, permeablized with 0.5% (v/v) NP40 in PBS for 10 min and then incubated with 1% (w/v) 432 
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bovine serum albumin in PBS for 45 min to block nonspecific protein binding. Cells were 433 
resuspended in FACS buffer (PBS containing 3% v/v FBS, 0.07% w/v NaN3), then incubated with 434 
specific primary antibodies to hexon or E2A DBP followed by Alexa488-conjugated secondary 435 
antibody. Washed cells in FACS buffer were analysed using a FACSCAN (BectonDickinson) and 436 
WinMDI software. Immunofluorescence analysis was performed as previously described (Leppard & 437 
Everett, 1999); images were collected with a Leica SP5 confocal microscope system and processed 438 
using Leica confocal software. Total RNA was isolated and mRNA quantified by RT-qPCR as previously 439 
described (Chen et al., 2015) using the following primers and amplicons: ISG56 and IL-6 (Chen et al., 440 
2015); E1A (113 bp, Ad genome 1422-1534) and hexon (137 bp, 21540-21576) (Schreiner et al., 441 
2013); PML-II 5’AGGCAGAGGAACGCGTTGT and 5’GGCTCCATGCACGAGTTTTC (70 bp); HSP70 (Tanaka 442 
et al., 2007); HSPA1A, HSPA1B, HSPA5, HSPA6, and HSP60 (www.rtprimerdb.org). 443 
Interferon activity and luciferase reporter assays 444 
MLP and L4P activity was determined in luciferase reporter assays as described (Morris & Leppard, 445 
2009; Wright et al., 2015). IFNβ promoter activity was measured by transfecting IFNβ-Luc (King & 446 
Goodbourn, 1994) in the presence of either wild-type or mutant E4 Orf3 expression plasmids (Hoppe 447 
et al., 2006) and pcDNAHisLacZ as an internal control for 24 h and stimulating by transfection with 448 
poly(I:C) for a further 8 h, otherwise as previously described (Chen et al., 2015; Morris & Leppard, 449 
2009). IFN activity in cell culture fluids was measured by plaque-reduction assay using infection of 450 
VERO cells by Semliki Forest virus (SFV). Subconfluent 12 well cultures were incubated for 24 h with 451 
either standard IFNα or with an unknown sample at 1 in 10 dilution, both in normal growth medium. 452 
After 24 h, cells were infected with 25 plaque-forming units of SFV, overlaid with agar-solidified 453 
medium and then fixed after 48 h incubation and plaques detected with crystal violet. All 454 
determinations were made in triplicate. Alternatively, IFN activity was determined by measuring the 455 
stimulation of pISRE-Luc by IFN-containing samples for 20 h in a luciferase reporter assay (Chen et 456 
al., 2015).  457 
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Figures  695 
 696 
Fig. 1. HelaΔII cells show physical and functional knockdown of PML-II.  (a) Phase -contrast 697 
microscopic images of control Hela and shRNA Hela cells; scale bar 100 µm. (b,c,d) HelaEV and 698 
HelaΔII cells were plated for 24 h, then RNA or protein samples were harvested. (b) PML-II mRNA 699 
was detected by RT-qPCR; results are normalized to the level detected in HelaEV cells and are the 700 
means and standard deviation of 3 technical replicates. (c) PML-II protein was detected by western 701 
blotting. (d) IL-6 and ISG56 mRNAs were analysed as in (b).  702 
 703 
 704 
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 705 
Fig. 2. Removal of PML-II increases Ad5 protein expression and virus yield. (a) HelaEV and HelaΔII 706 
cells were infected with wild type Ad5 at moi of 5, and total protein extracts at various times post-707 
infection analysed by western blotting. Upper panel: Ad5 late protein; middle panels: Ad5 E1B 55K 708 
and E2A DNA binding protein (DBP) ; lower panel: GAPDH. The 24 h samples were loaded at a 1:100 709 
dilution compared to the earlier time points. (b) Total protein extracts of HelaEV and standard Hela 710 
cells, infected for 20 h as in (a), were analysed for hexon expression. (c) Adenovirus gene expression 711 
by FACS analysis. Upper panel: late gene expression; lower panel: DBP expression; grey curves are 712 
the background (mock infected cells) while the black curves represent infected cells; the % of 713 
fluorescence-positive cells and their mean fluorescence intensity (MFI) are indicated on each panel. 714 
(d) Total virus in infected culture lysates was determined by fluorescent focus assay. Error bars show 715 
the standard deviation of replicates within an experiment; the experiment shown is representative 716 
of multiple experiments. 717 
 718 
 719 
 720 
 721 
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 722 
Fig. 3 PML-II inhibits Ad5 infection by both IFN-dependent and independent mechanisms. HelaEV 723 
and HelaΔII cells were plated for 24 h, transfected with 62.5 pmol/ml siRNA as indicated for 48 h and 724 
then either stimulated with poly I:C for 16 h (a, b) or infected with Ad5 wt300 at moi of 5 for 20 h (c), 725 
after which samples were prepared for analysis. (a) IRF3 protein or GAPDH (loading control) was 726 
detected by western blot. (b) RT-qPCR analysis detecting ISG56 mRNA; results are the means and 727 
standard deviation of 3 technical replicates. (c) As panel (a), but detecting hexon protein using anti-728 
late protein polyclonal antibodies.  729 
 730 
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 731 
Fig. 4 Adenovirus E4 Orf3 inhibits IFN production and IFNβ promoter activation. (a) HEK293 cells 732 
were infected at a multiplicity of 10 p.f.u./cell with wild type Ad5 (wt300) or mutant inOrf3, or mock-733 
infected. Media was harvested at 8 h p.i. and IFN activity measured by plaque-reduction assay. (b) As 734 
panel (a) but using media from Ad5-infected MRC5 fibroblasts harvested at 16 h p.i. (c) Media from 735 
HEK293 cell cultures infected as in (a) was harvested at 6 h p.i. and IFN activity measured using an 736 
ISRE-luciferase reporter construct in HEK293 cells. Known amounts of recombinant IFNα were 737 
analyzed in parallel to provide a standard curve. (d) HEK293 cells were transfected with IFNβ 738 
promoter luciferase reporter and β-galactosidase control plasmids together with PML-IIΔRBCC (125 739 
ng) and from 125 – 625 ng E4 Orf3 plasmid as appropriate and then stimulated with poly(I:C) and 740 
reporter activities assayed 8 h later. (e-i) HEK293 cells were transfected with reporter plasmids as in 741 
(d) plus 150 – 600 ng (150 – 750 ng, panels e, g) of either wild-type E4 Orf3 plasmid (e), or mutant E4 742 
Orf3 R100A (f), N82A (g), L103A (h) or D105A-L106A (i), and then stimulated or not with poly(I:C) as 743 
indicated and assayed as in panel (d). Data are the means and standard deviation of three biological 744 
replicates. 745 
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 746 
 747 
Fig. 5. Role of E4 Orf3 in the response of Ad5 to PML-II depletion and IFN-α. HelaEV and HelaΔII 748 
cells were either mock-treated (lanes 1, 2, 4, 6, 7, 9) or treated with 1000 U/ml of IFN-α for 24 h (+I; 749 
lanes 3, 5, 8, 10), then mock-infected or infected with Ad5 wt300 or inOrf3 as indicated for 20 h. 750 
Total protein lysates were collected and analysed by western blotting for Ad5 late proteins (upper) 751 
or GAPDH (lower). Hexon protein bands were quantified using QuantityOne software, normalized to 752 
GAPDH and expressed relative to the value for wt300 in HelaEV cells. 753 
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 754 
Fig. 6. Elevated Hsp70 enhances the expression of Ad5 proteins when PML-II is reduced. (a, e) 755 
Samples were harvested from HelaEV and HelaΔII cells and analysed for HSP70 mRNA (a) or a 756 
selection of HSP mRNAs (e) by RT-qPCR, or (a, lower) for HSP70 protein by western blot. (b) Hela 757 
cells were transfected or not with 125 pmol/ml siRNA as indicated and RNA harvested after 48 h for 758 
analysis of HSP70 mRNA by RT-qPCR. (c) HelaEV and HelaΔII cells were transfected with 125 pmol/ml 759 
HSP70 or control siRNA for 48 h, then infected with Ad5 wt300 for 20 h before RNA was harvested 760 
and analysed for hexon mRNA by RT-qPCR. (d) HelaΔII cells were treated with siRNA and infected as 761 
in (c), then lysed and analysed by western blotting as in Fig. 5. In (a - c), data were standardized to an 762 
internal control and then normalized to values from: (a) HelaEV; (b) siControl-treated Hela; (c) 763 
siControl-treated HelaEV. Panel (e) shows mRNA amounts measured separately for each amplicon, 764 
standardized in each case to an internal control. Graphs show the means and standard deviation of 3 765 
technical replicates. 766 
 767 
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 770 
 771 
 772 
Fig. 7. Effects of elevated Hsp70 on NF-kB signalling do not cause enhanced Ad5 gene expression. 773 
(a) HelaEV cells were treated with HSP70 or control siRNA as in Fig. 6(c), then infected with Ad5 774 
wt300 at moi of 5 for 20 h and ISG56 mRNA quantified by RT-qPCR. (b, d) Cells as indicated were 775 
treated or not with 50 ng TNFα for 1 h (b) or with 100 nM of the NF-κB inhibitor QNZ for 45 min (d), 776 
then infected with Ad5 wt300 at moi of 5 for 20 h. Protein samples were harvested and analysed for 777 
late protein expression by western blot. (c) HelaEV cells, treated with siRNA as in (a) were treated 778 
with TNFα as in (b), infected with Ad5 wt300 as in (a) and hexon mRNA quantified by RT-qPCR. 779 
Results in panels a, c are the means and standard deviation of 3 technical replicates. 780 
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 781 
 782 
Fig. 8. Hsp70 promotes nuclear accumulation of Ad5 hexon but has no effect on late promoter 783 
activity. (a) HelaΔII cells were treated with HSP70 or control siRNA as in Fig. 6(c), then infected with 784 
Ad5wt300 at moi of 5 for 16 hours. Cytoplasmic and nuclear fractions were analysed by SDS-PAGE 785 
and western blotting. Replicate blots were probed with antibodies to the proteins indicated and 786 
bands quantified as in Fig 5, normalized to GAPDH (cytoplasmic) or SP1 (nuclear). (b) Hela cells were 787 
treated with siRNA as in (a) and then transfected with MLP or L4P luciferase reporter. Luciferase 788 
activity was measured after 20 h and normalized to a β-galactosidase transfection control as 789 
described (Wright et al., 2015). (c) HelaEV and HelaΔII cells were infected with wild type Ad5 at moi 790 
of 5, and total protein extracts analysed by western blotting at 20 h p.i. for the proteins indicated. 791 
